RS-102221 is a drug developed by Hoffmann–La Roche which was one of the first compounds discovered that acts as a potent and selective antagonist at the serotonin 5-HT2C receptor with around 100x selectivity over the closely related 5-HT2A and 5-HT2B receptors.
This page contains content from the copyrighted Wikipedia article "RS-102221"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
